Abstract: Particular anti-LFL2 antibody compositions are provided herein. These antibodies may be used for diagnosis, prognosis, therapeutic monitoring and treatment of cancer, especially breast cancer, head/neck cancer, lung cancer, ovarian cancer, stomach cancer and pancreatic cancer. Furthermore, anti-LFL2 antibodies are provided herein which target the LFL2 stump remaining after proteolytic cleavage of the extracellular domain of LFL2. Additionally, anti-LFL2 antibodies are provided herein which target the stroma surrounding cancer tumors, wherein said stroma-targeting anti-LFL2 antibodies disrupt the integrity of the stroma surrounding the cancer tumor, and also make the stroma more permeable to chemotherapeutic agents and other molecular drug agents that target tumor cells.

Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.

Abstract: GPR64 antibody compositions are provided. These antibodies may be used for diagnosis or treatment of cancer, especially ovarian cancer, Ewing's sarcoma, uterine cancer, and other GPR64 expressing tumor types.

Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.

Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.

Abstract: GPR64 antibody compositions are provided. These antibodies may be used for diagnosis or treatment of cancer, especially ovarian cancer, Ewing's sarcoma, uterine cancer, and other GPR64 expressing tumor types.

Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.

Abstract: Particular anti-LFL2 antibody compositions are provided herein. These antibodies may be used for diagnosis, prognosis, therapeutic monitoring and treatment of cancer, especially breast cancer, head/neck cancer, lung cancer, ovarian cancer, stomach cancer and pancreatic cancer. Furthermore, anti-LFL2 antibodies are provided herein which target the LFL2 stump remaining after proteolytic cleavage of the extracellular domain of LFL2. Additionally, anti-LFL2 antibodies are provided herein which target the stroma surrounding cancer tumors, wherein said stroma-targeting anti-LFL2 antibodies disrupt the integrity of the stroma surrounding the cancer tumor, and also make the stroma more permeable to chemotherapeutic agents and other molecular drug agents that target tumor cells.

Abstract: The present invention provides methods for direct killing of cancer cells using anti-?5?1 antibodies. Generally, the method comprises contacting a cancer cell that expresses ?5?1 on its surface with an anti-?5?1 antibody, and thereby inducing the death of the cancer cell. The methods of the invention may be employed at an early stage of cancer development in a patient to prevent tumor establishment. In addition, the methods may be used to treat previously formed tumors especially in cancer that have not proven susceptible to anti-angiogenesis therapy. The methods may be employed as a combination therapy of anti-?5?1 antibodies together with cancer chemotherapeutic agents or other molecular-based cancer therapeutic agents.

Abstract: The invention relates to the identification of chemokine receptors associated with cancers and other diseases. The invention also provides for the use of antagonists of the CXCR4 protein in diagnosis and therapy of proliferative disease.

Abstract: The invention relates to the identification and generation of antibodies that specifically bind to SLC15A2 protein. The disclosed anti-SLC15A2 antibodies and compositions comprising them may be used for diagnosis, prognosis and therapy of cancer (including metastatic cancer) or fibrotic conditions, e.g., ovarian cancer, cervical cancer, prostate cancer, uterine cancer, lung cancer, lung fibrosis, and glioblastoma. The disclosed antibodies include conjugates with cytotoxic effector components that are useful for cancer therapy.

Abstract: GPR64 antibody compositions are provided. These antibodies may be used for diagnosis or treatment of cancer, especially ovarian cancer, Ewing's sarcoma, uterine cancer, and other GPR64 expressing tumor types.

Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.

Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.

Abstract: The present invention provides ORFX, a novel isolated polypeptide, as well as a polynucleotide encoding ORFX and antibodies that immunospecifically bind to ORFX or any derivative, variant, mutant, or fragment of the ORFX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the ORFX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as to others uses.